IN2014MN01988A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01988A
IN2014MN01988A IN1988MUN2014A IN2014MN01988A IN 2014MN01988 A IN2014MN01988 A IN 2014MN01988A IN 1988MUN2014 A IN1988MUN2014 A IN 1988MUN2014A IN 2014MN01988 A IN2014MN01988 A IN 2014MN01988A
Authority
IN
India
Prior art keywords
group
aromatic heterocyclic
monocyclic
heterocyclic group
hydrocarbon ring
Prior art date
Application number
Inventor
Atsunobu Sakamoto
Naoki Tanaka
Takeshi Fukuda
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2014MN01988A publication Critical patent/IN2014MN01988A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1) or the like. (In general formula (1) R represents Q Q X Q Q X Q Y Q; Q represents a monocyclic or bicyclic aromatic heterocyclic group; each of Q and Q represents an aromatic hydrocarbon ring group or a monocyclic aromatic heterocyclic group; X represents CONH CONHCH CHOCH NHCHCH or the like; Y represents a single bond O (CH) or O (CH) ; each of m and n represents an integer of 1 3; R represents H or an alkyl group; and R represents H an alkoxycarbonyl group a carboxy group an aromatic hydrocarbon ring group or a monocyclic aromatic heterocyclic group.)
IN1988MUN2014 2012-03-30 2013-03-29 IN2014MN01988A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012079858 2012-03-30
PCT/JP2013/059656 WO2013147215A1 (en) 2012-03-30 2013-03-29 4-alkanoylamino-3-pyrazolone derivative

Publications (1)

Publication Number Publication Date
IN2014MN01988A true IN2014MN01988A (en) 2015-07-10

Family

ID=49260456

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1988MUN2014 IN2014MN01988A (en) 2012-03-30 2013-03-29

Country Status (11)

Country Link
US (1) US9212170B2 (en)
EP (1) EP2832733B1 (en)
JP (1) JP6126078B2 (en)
KR (1) KR20140138208A (en)
CN (1) CN104321318A (en)
CA (1) CA2869130A1 (en)
ES (1) ES2699404T3 (en)
HK (1) HK1204621A1 (en)
IN (1) IN2014MN01988A (en)
TW (1) TW201400470A (en)
WO (1) WO2013147215A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017114765A (en) * 2014-04-25 2017-06-29 大正製薬株式会社 Heteroaryl compound substituted with triazolyl
CN112375072B (en) * 2020-09-28 2021-05-28 上海长征富民金山制药有限公司 Pyrazolone derivative, injection and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
DE102005019712A1 (en) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102006050515A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102007044032A1 (en) 2007-09-14 2009-03-19 Bayer Healthcare Ag New substituted heteroaryl compounds are hypoxia-inducible factor prolyl-4-hydroxylase inhibitors useful to treat and/or prevent e.g. circulatory heart diseases, heart failure, anemia, chronic kidney diseases and renal failure
JP5341069B2 (en) 2008-04-22 2013-11-13 第一三共株式会社 5-hydroxypyrimidine-4-carboxamide compounds
DK2382205T3 (en) * 2008-12-29 2014-07-28 Sanofi Sa 2-PYRIDIN-2-YL-PYRAZOL-3 (2H) -ON DERIVATIVES, PREPARING THEREOF AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS
MA32978B1 (en) * 2008-12-29 2012-01-02 Sanofi Sa Derivatives 2- pyridine -2-yl-pyrazole -3 (2h) en, prepared and applied in treatment
JP2011088840A (en) * 2009-10-21 2011-05-06 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising 5-hydroxypyrimidine-4-carboxamide compound
JP2011105708A (en) * 2009-10-21 2011-06-02 Daiichi Sankyo Co Ltd Pharmaceutical composition containing 5-hydroxypyrimidine-4-carboxamide compound

Also Published As

Publication number Publication date
EP2832733B1 (en) 2018-08-29
TW201400470A (en) 2014-01-01
WO2013147215A1 (en) 2013-10-03
CN104321318A (en) 2015-01-28
US20150011552A1 (en) 2015-01-08
EP2832733A1 (en) 2015-02-04
HK1204621A1 (en) 2015-11-27
US9212170B2 (en) 2015-12-15
KR20140138208A (en) 2014-12-03
JP6126078B2 (en) 2017-05-10
EP2832733A4 (en) 2015-09-30
ES2699404T3 (en) 2019-02-11
JPWO2013147215A1 (en) 2015-12-14
CA2869130A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IN2014MN02574A (en)
PH12015500263A1 (en) New bicyclic derivatives
WO2014008458A3 (en) N-substituted benzamides and methods of use thereof
IN2015DN00598A (en)
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MY163083A (en) Solid forms of a pharmaceutically active substance
WO2014100764A3 (en) Methods of inhibiting prmt5
WO2014011911A3 (en) Irak inhibitors and uses thereof
UA113643C2 (en) N-CYCLYLAMIDES AS NEMATOCIDES
MX2015002040A (en) Deuterated baricitinib.
RS54730B1 (en) Inhibitors of beta-secretase
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MX2015012629A (en) Imidazo pyridine compounds.
CR20140306A (en) FLUORMETIL -5,6-DIHIDRO-4H- [1,3] OXAZINES
IN2012DE00621A (en)
WO2012101011A3 (en) New aryl-benzocycloalkyl amide derivatives
MX2015017156A (en) Bace inhibitors.
MX2017016030A (en) Substituted dihydropyrrolopyrazole derivative.
IN2012DE00620A (en)
IN2014DN07996A (en)
EA201370149A1 (en) ANTAGONISTS RECEPTOR
MX366983B (en) 1,5-naphthyridine derivatives and melk inhibitors containing the same.
PH12015501146A1 (en) Hydantoin derivative
IN2014DN08653A (en)
WO2014062428A8 (en) Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds